What is Lifesci Capital’s Forecast for Surrozen Q1 Earnings?

Surrozen, Inc. (NASDAQ:SRZN) – Stock analysts at Lifesci Capital reduced their Q1 2026 EPS estimates for Surrozen in a research note issued on Monday, March 23rd. Lifesci Capital analyst P. Dolezal now anticipates that the company will post earnings per share of ($2.06) for the quarter, down from their previous forecast of ($1.82). The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. Lifesci Capital also issued estimates for Surrozen’s Q2 2026 earnings at ($2.10) EPS, Q3 2026 earnings at ($2.17) EPS, Q4 2026 earnings at ($1.23) EPS and FY2026 earnings at ($4.73) EPS.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price target on shares of Surrozen in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective (up from $32.00) on shares of Surrozen in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Surrozen Stock Up 4.6%

Shares of SRZN stock opened at $26.14 on Thursday. The company’s fifty day simple moving average is $24.34 and its two-hundred day simple moving average is $18.81. Surrozen has a 52 week low of $5.90 and a 52 week high of $29.59. The stock has a market cap of $224.02 million, a P/E ratio of -0.78 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The company had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%.

Insider Transactions at Surrozen

In related news, Director Tim Kutzkey purchased 18,052 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were bought at an average price of $19.60 per share, for a total transaction of $353,819.20. Following the acquisition, the director owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This represents a 1.81% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Group Gp Lp Column III purchased 18,052 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was bought at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the transaction, the insider owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. The trade was a 1.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 330,291 shares of company stock worth $7,478,785. 45.18% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Surrozen

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the period. Stonepine Capital Management LLC boosted its position in shares of Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the period. Stempoint Capital LP grew its stake in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Surrozen during the second quarter valued at approximately $536,000. Finally, Braidwell LP purchased a new stake in shares of Surrozen in the second quarter worth approximately $1,252,000. 66.57% of the stock is currently owned by institutional investors.

Surrozen News Summary

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Major shareholder TCG Crossover GP II purchased 106,658 shares on March 24 at an average $24.69, increasing its stake ~16.9% to 736,554 shares — a strong insider-buy signal that can support the stock. SEC Filing
• Positive Sentiment: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90, a smaller follow-on purchase that further signals insider confidence. SEC Filing
• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating with a $40 price target — a materially higher valuation that may attract buyers. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and raised its target to $36. Its analyst also issued a FY2030 EPS forecast (-$3.54), notably less negative than the broader consensus, signaling a more optimistic long-term view. TickerReport
• Neutral Sentiment: Short-interest reports for March show zero shorted shares and a 0.0 days-to-cover metric, but the entries include NaN and look inconsistent — treat this as unreliable data rather than a clear market signal.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.